NASDAQ:DYAX Dyax (DYAX) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free DYAX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$38.41▼$38.4150-Day Range N/A52-Week Range$14.06▼$38.56VolumeN/AAverage Volume5.25 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Dyax alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Dyax Stock (NASDAQ:DYAX)Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… DYAX Stock News HeadlinesSeptember 7, 2023 | finanznachrichten.deAnokion SA: Anokion Strengthens its Senior Leadership with Promotions and New AppointmentSeptember 7, 2023 | finance.yahoo.comAnokion Strengthens its Senior Leadership with Promotions and New AppointmentApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.July 17, 2023 | msn.comMost immigrants in West Virginia are from these countriesJuly 17, 2023 | msn.comIs David Corenswet A Good Fit For Superman? Here's How /Film Readers FeelJuly 17, 2023 | msn.comMost immigrants in Virginia are from these countriesJuly 11, 2023 | benzinga.comCytophage Technologies Inc. Board of Directors Welcomes New Member and Board AdvisorJuly 7, 2023 | msn.comJanhvi and Khushi Kapoor shower love Boney Kapoor as he cooks breakfast for AnshulaApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.May 16, 2023 | marketwatch.comNext-Generation Antibody Therapeutics Market Price & News with Share ForecastMay 12, 2023 | marketwatch.comS-1: NutriBand Inc.May 10, 2023 | finance.yahoo.comKorro Strengthens Leadership Team with Appointment of Shelby Walker as General CounselMarch 24, 2023 | insidermonkey.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Q4 2022 Earnings Call TranscriptMarch 14, 2023 | marketwatch.comNext-Generation Antibody Therapeutics Market Analysis: Understanding The Current State and Future Trends 2023-2028March 13, 2023 | marketwatch.comNext-Generation Antibody Therapeutics Market Outlook and Forecast to 2029 with Top Countries DataMarch 8, 2023 | marketwatch.comNext Generation Antibody Therapeutics Market Size, Latest Trends, Share, Top Players, Revenue and Forecast 2028March 4, 2023 | msn.comHOOPS RECAP: In UT’s first full game without Zakai Ziegler, Tennessee fails to hit a shot during the final six minutes of the game, loses to Auburn 79-70February 26, 2023 | marketwatch.comNext-Generation Antibody Therapeutics Market Size, Analysis with Key Players having Regional Statistics and Application Forecast to 2028January 11, 2023 | msn.comPeter Hotez on new COVID XBB1.5 variant: 'People are saying this will be mild. It's not mild'January 2, 2023 | thestreet.comDrug Giant Shire Snaps Up Biotech Dyax for $5.9 BillionDecember 24, 2022 | seekingalpha.comAstria Therapeutics: Tailwinds Building With Novel Treatment ParadigmDecember 13, 2022 | msn.comNoisy toys and hearing damage with Ascent Audiology & HearingNovember 28, 2022 | msn.comCommentary: There are those who get out of the water when there’s a shark, and those who get inNovember 18, 2022 | msn.comInstagrammer shares how their tiny ‘kitchen composter’ makes food waste disappear: ‘Everyone needs one’November 17, 2022 | msn.comNo more deaths recorded in BristolNovember 2, 2022 | msn.comMartin Lewis says thousands being ripped off when it comes to savings ratesOctober 14, 2022 | seekingalpha.comKalVista: Another Setback But The Key Value Driver Is Still In PlaceSee More Headlines Receive DYAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyax and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/28/2015Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:DYAX CUSIP26746E10 CIK907562 Webwww.dyax.com Phone+1-617-2505769FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report DYAX Stock Analysis - Frequently Asked Questions How were Dyax's earnings last quarter? Dyax Corp (NASDAQ:DYAX) posted its quarterly earnings data on Wednesday, October, 28th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.08). The biopharmaceutical company had revenue of $24.70 million for the quarter, compared to analysts' expectations of $24.96 million. Dyax's revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.01) EPS. What other stocks do shareholders of Dyax own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dyax investors own include (KRFT) (KRFT), ASML (ASML), Bank of Nova Scotia (BNS), DOW (DOW), Dover Motorsports (DVD), Novavax (NVAX), Prudential (PRU), Standard Chartered (STAN), Anthera Pharmaceuticals (ANTH) and Ariad Pharmaceuticals (ARIA). This page (NASDAQ:DYAX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport SocietyMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyax Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
